Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome

NCT00023621 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-melanomatous Skin Cancer

Interventions

DRUG: celecoxib

Sponsor

University of California, San Francisco

Collaborators

[object Object]